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We previously showed that the kringle domains of plasmin and angiostatin, the N-terminal four kringles (K1–4) of plasminogen,
directly bind to integrins. Angiostatin blocks tumor-mediated angiogenesis and has great therapeutic potential. Angiostatin
binding to integrins may be related to the antiinflammatory action of angiostatin. We reported that plasmin induces
signals through protease-activated receptor (PAR-1), and plasmin-integrin interaction may be required for enhancing plasmin
concentration on the cell surface, and enhances its signaling function. Angiostatin binding to integrin does not seem to induce
proliferative signals. One possible mechanism of angiostatin’s inhibitory action is that angiostatin suppresses plasmin-induced
PAR-1 activation by competing with plasmin for binding to integrins. Interestingly, plasminogen did not interact with αvβ3,
suggesting that the αvβ3-binding sites in the kringle domains of plasminogen are cryptic. The kringle domain of urokinase-type
plasminogen activator (uPA) also binds to integrins. The uPA-integrin interaction enhances uPA concentrations on the cell surface
and enhances plasminogen activation on the cell surface. It is likely that integrins bind to the kringle domain, and uPAR binds
to the growth factor-like domain (GFD) of uPA simultaneously, making the uPAR-uPA-integrin ternary complex. We present a
docking model of the ternary complex.
1. The Kringle Domains of Plasmin
Interact with Integrins
The integrins are a superfamily of cell adhesion receptors that
bind to extracellular matrix ligands, cell-surface ligands, and
soluble ligands. They are transmembrane αβ heterodimers
and at least 18 α and eight β subunits are known in humans,
generating 24 heterodimers [1]. The α and β subunits have
distinct domain structures, with extracellular domains from
each subunit contributing to the ligand-binding site of the
heterodimer. The sequence arginine-glycine-aspartic acid
(RGD)was identified as a general integrin-bindingmotif, but
individual integrins are also specific for particular protein
ligands. Immunologically important integrin ligands are the
intercellular adhesion molecules (ICAMs), immunoglobulin
superfamily members present on inflamed endothelium and
antigen-presenting cells. On ligand binding, integrins trans-
duce signals into the cell interior; they can also receive intra-
cellular signals that regulate their ligand-binding affinity.
Angiostatin, a proteolytic fragment of plasminogen, con-
tains either the first three or four kringle domains of plas-
minogen and is a potent inhibitor of tumor-induced angio-
genesis in animal models [2, 3]. Angiostatin has promising
therapeutic potential and is now in clinical trials. Plas-
minogen is first converted to the two-chain serine protease
plasmin by cleavage of a single Arg561-Val562 peptide bond
by urokinase-type plasminogen activator (uPA), and plasmin
serves as both the substrate and enzyme for the generation
of angiostatin [4]. Several other mechanisms have been
proposed for the generation of angiostatin from the plas-
minogen molecule [5]. The antiangiogenic functions of plas-
minogen kringles have been extensively studied using recom-
binant plasminogen kringles and kringle fragments pro-
duced by elastolytic processing of native plasminogen.
Smaller fragments of angiostatin display differential effects
on the suppression of endothelial cell growth [6].
We found that bovine arterial endothelial (BAE) cells
adhere to angiostatin in an integrin-dependent manner and
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that integrins αvβ3, α9β1, and to a lesser extent α4β1, specif-
ically bind to angiostatin. αvβ3 is a predominant receptor for
angiostatin on BAE cells, since a function-blocking antibody
to αvβ3 effectively blocks adhesion of BAE cells to angio-
statin, but an antibody to α9β1 does not. ε-Aminocaproic
acid, a Lys analogue, effectively blocks angiostatin binding
to BAE cells, indicating that an unoccupied Lys-binding site
of the kringles may be required for integrin binding. It is
known that other plasminogen fragments containing three
or five kringles (K1–3 or K1–5) have an antiangiogenic effect,
but plasminogen itself does not. We found that K1–3 and
K1–5 bind to αvβ3, but plasminogen does not. These results
suggest that the anti-angiogenic action of angiostatin may
be mediated via interaction with αvβ3. Angiostatin binding
to αvβ3 does not strongly induce stress-fiber formation,
suggesting that angiostatin may prevent angiogenesis by
perturbing the αvβ3-mediated signal transduction that may
be necessary for angiogenesis [7].
Plasmin, the parent molecule of angiostatin and a major
extracellular protease, induces platelet aggregation, migra-
tion of peripheral blood monocytes, and release of arachi-
donate and leukotriene from several cell types [8]. We found
that plasmin specifically binds to αvβ3 through the kringle
domains and induces migration of endothelial cells. In
contrast, angiostatin does not induce cell migration. Notab-
ly, angiostatin, anti-αvβ3 antibodies, RGD-peptide, and a
serine protease inhibitor effectively block plasmin-induced
cell migration. These results suggest that plasmin-induced
migration of endothelial cells requires αvβ3 and the catalytic
activity of plasmin and that this process is a potential target
for the inhibitory activity of angiostatin [9].
We found that plasmin specifically interacts with integrin
(α9β1) and that plasmin induces migration of cells express-
ing recombinant α9β1 (α9-Chinese hamster ovary (CHO)
cells). Migration was dependent on an interaction of the
kringle domains of plasmin with α9β1 as well as the catalytic
activity of plasmin. Angiostatin, representing the kringle
domains of plasmin, alone did not induce the migration of
α9-CHO cells, but simultaneous activation of the G protein-
coupled protease-activated receptor (PAR)-1 with an agonist
peptide induced the migration on angiostatin, whereas PAR-
2 or PAR-4 agonist peptides were without effect. Further-
more, a small chemical inhibitor of PAR-1 (RWJ 58259) and
a palmitoylated PAR-1-blocking peptide inhibited plasmin-
induced migration of α9-CHO cells. These results suggest
that plasmin induces migration by kringle-mediated binding
to α9β1 and simultaneous proteolytic activation of PAR-1
[10]. It is likely that other integrins that bind to plasmin may
exert similar effects on plasmin signaling.
We propose a model (Figure 1) in which (1) upon plas-
minogen activation, integrin-binding site in plasmin is
exposed. Note that plasminogen does not bind to integrins
αvβ3 or α9β1. (2) Once activated, plasmin is able to bind
to integrins on the cell surface through the kringle domains
(since integrin-binding sites are exposed) and proteolytically
activates PAR-1, which induces intracellular signaling. Plas-
min is concentrated to the cell surface through integrin bind-
ing, and this process is probably critical since plasmin has
much lower affinity to PAR-1 than thrombin. Angiostatin,
in contrast, binds to integrins, but does not activate PAR-
1. Angiostatin is expected to suppress plasmin action by
competing with plasmin for binding to integrins.
It has been reported that integrins αMβ2 [11], αDβ2 [12],
and α5β1 [13] bind to plasminogen, while we did not detect
binding of αvβ3 or α9β1 to plasminogen. One possibility is
that integrins αMβ2, αDβ2, and α5β1 recognize plasminogen
in the ways different from those of αvβ3 or α9β1. Another
possibility is that integrin-binding sites in plasminogen
(perhaps kringle domains) are exposed in partially denatured
plasminogen. Supporting the second possibility we observed
that freshly prepared plasminogen did not significantly bind
to αvβ3, but plasminogen binding to αvβ3 appeared to
increase as plasminogen preparations aged (data not shown).
This issue should be clarified in future studies.
In conclusion, the kringle domains in plasmin are involv-
ed in direct integrin binding, in addition to binding to the C-
terminal Lysine residues of many proteins, and playing a role
in inducing intracellular signals through proteolytic activa-
tion of PAR-1. The kringle-integrin interaction may enhance
the cell surface concentration of plasmin, or directly induce
intracellular signals through outside-in integrin signaling.
Interestingly, plasminogen does not interact with integrins
αvβ3 or α9β1 (possibly the integrin-binding sites are cryptic
in plasminogen) (Figure 1) Based on our results on the
plasmin kringle-integrin interaction, we hypothesized that
the kringle domains of other serine proteases may interact
with integrins and the interaction may play a role in their
functions. Consistent with this idea, kringle domains from
other proteins such as tissue-type plasminogen activator
(tPA) [14] and apolipoprotein [15] have been reported to
interact with integrins. This suggests that kringle-integrin
interaction is a common mechanism in kringle-containing
proteins.
2. uPA Kringle-Integrin Interaction
uPA is a highly restricted serine protease that converts the
zymogen plasminogen to active plasmin. uPA binds with
high affinity to a cell-surface uPA receptor (uPAR) that
has been identified in many cell types. uPAR is a glyco-
sylphosphatidylinositol- (GPI-) anchored 35–55 kDa glyco-
protein. This system mediates pericellular proteolysis of
extracellular matrix proteins including fibrin degradation
(fibrinolysis) and plays an important role in cancer, inflam-
mation, and immune responses [16–19]. The single chain
form of uPA has three independently folded domains: the
growth factor-like domain (GFD) (residue 1–46), kringle
(residue 47–135) domain, and serine protease domain
(residue 159–411). Enzymatic digestion of single chain-uPA
yields an amino terminal fragment (ATF), which consists of
the GFD and kringle domains, and the low molecular weight
fragment (LMW-uPA), which consists of the serine protease
domain. The uPAR-binding site of uPA is located in the GFD
domain [20]; this binding is stabilized by the kringle [21].
It has generally been accepted that uPA signaling involves its
binding to uPAR through its GFD [22].
uPA binding to uPAR on the cell surface facilitates activa-
tion of plasminogen to plasmin in vitro by increasing the rate
Journal of Biomedicine and Biotechnology 3
Kringles
Angiostatin (K1-3)
RGD peptides
Anti-integrin antibodies
Antikringle antibodies
Plasmin
Serine protease
inhibitors
PAR antagonists
PARs
Migration
Catalytic
domain
Integrins
(e.g., αvβ3)
Figure 1: A model of plasmin-induced cell migration and the potential mechanism of angiostatin action. uPA activates plasminogen to
plasmin pericellularly. Plasmin is accumulated on the cell surface by binding to integrins and stabilized. Free plasmin would be rapidly
inactivated by circulating serine protease inhibitors (e.g., β2-antiplasmin). The catalytic activity of plasmin on the cell surface is directly
involved in signal transduction, possibly through activating G-protein coupled PARs. The binding of the kringle domain may not be directly
involved in signaling through integrin pathways. Angiostatin effectively blocks plasmin-induced cell migration possibly by competing with
plasmin for binding to integrins. Aprotinin, a serine protease inhibitor, also effectively blocks migration. It should be noted that other
antiangiogenic agents, RGD-peptide and anti-αvβ3, are effective inhibitors of this process.
of pro-uPA activation by plasmin, by decreasing the apparent
Km of uPA to plasmin, and by increasing the Kcat/Km of
uPA to plasmin [23]. It is interesting that uPA-knockout
mice do not have major thrombotic disorders [24]. This is
probably because of the redundant fibrinolytic function by
tPA. Indeed, combined uPA and tPA knockout mice show
extensive thrombotic disorders very similar to those observed
in plasminogen-knockout mice, but these are rarely detected
in animals lacking uPA or tPA alone [25]. In contrast to
uPA, studies performed in uPAR-knockout mice do not
really support a major role of uPAR in fibrinolysis. Fibrin
deposits are found within the livers of mice with a combined
deficiency in uPAR and tPA, but not in uPAR-knockout mice,
indicating a minor role for uPAR in plasminogen activation
[25]. The extraordinarily mild consequences of combined
uPAR and tPA deficiency raised the question of whether there
are other receptors for uPA that might facilitate plasminogen
activation [19, 25].
Besides plasminogen activation, uPA has been shown to
induce the adhesion and chemotactic movement of myeloid
cells [26, 27], to induce cell migration in human epithelial
cells [28] and bovine endothelial cells [29], and to promote
cell growth [30–32]. Notably these signaling functions of uPA
do not require its proteolytic activity. Several studies suggest
that uPA has additional, unidentified cell-surface receptor(s)
other than uPAR that are involved in signaling events. For
example, blocking of uPA binding to uPAR using a mono-
clonal antibody or by depletion of cell surface uPAR with
phosphatidylinositol-specific phospholipase C (PIPLC) did
not inhibit uPA-induced mitogenic effects in smooth muscle
cells [33]. uPA-induced mitogenic effects in melanoma cells
are independent of high-affinity binding to uPAR, and this
suggests the existence of a low-affinity binding site on this
cell type based on the kinetic data [34]. The chemotactic
action of uPA on smooth muscle cells depends on its kringle
domain, and kinetic evidence indicates that these cells
express a lower-affinity kringle receptor distinct from uPAR
[35]. The isolated uPA kringle augments vascular smooth
muscle cell constriction in vitro [36] and in vivo [37]. Taken
together these observations all suggest that cells express uPA-
binding proteins (other than uPAR) that mediate signaling
from uPA.
We found that uPA binds specifically to integrin αvβ3
on CHO cells depleted of uPAR (Figure 2). The binding of
uPA to αvβ3 required the uPA kringle domain (Figure 3).
The isolated uPA kringle domain binds specifically to purif-
ied, recombinant soluble, and cell surface αvβ3, and other
integrins (α4β1 and α9β1), and induces migration of CHO
cells in an αvβ3-dependent manner. The binding of the uPA
kringle to αvβ3 and uPA kringle-induced αvβ3-dependent
cell migration is blocked by angiostatin. We studied whether
the binding of uPA to integrin αvβ3 through the kringle
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Figure 2: uPA binding to the cell surface in an integrin αvβ3-dependent and uPAR-independent manner [38]. (a) and (b) Depletion of
uPAR from the cell surface blocked uPA binding to uPAR-CHO cells, but did not affect uPA binding to β3-CHO cells. To deplete GPI-linked
uPAR on the cell surface, β3-CHO, uPAR-CHO, or control mock-transfected CHO cells were treated with PIPLC. The treatment removed
more than 95% of human uPAR from uPAR-CHO cells as determined by flow cytometry with anti-uPAR mAb 3B10 (data not shown). uPA
was immobilized to wells of 96-well microtiter plates at the indicated coating concentrations, and incubated with cells without (a) or with
(b) pretreatment with PI-PLC. Bound cells were quantified. (c) uPA binding to β3-CHO cells is specific to αvβ3 and the kringle domain.
uPA (200 nM coating concentration) was immobilized to wells of 96-well microtiter plates and incubated with β3-CHO cells in the presence
of mAb 16N7C2 (anti-β3), Ab 963 (anti-kringle), mAb UNG-5 (anti-LMW-uPA), or RGD or RGE peptides (100 μM).
domain plays a role in plasminogen activation. On CHO cell
depleted of uPAR, uPA enhances plasminogen activation in a
kringle and αvβ3-dependent manner (Figure 4). Endothelial
cells bind to andmigrate on uPA and uPA kringle in an αvβ3-
dependent manner. These results suggest that uPA binding
to integrins through the kringle domain plays an important
role in both plasminogen activation and uPA-induced intra-
cellular signaling. The uPA kringle-integrin interaction may
represent a novel therapeutic target for cancer, inflammation,
and vascular remodeling [38].
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Figure 3: The kringle domain of uPA mediates binding to αvβ3.
The uPA kringle domain was immobilized onto wells of 96-
well microtiter plates at the indicated coating concentrations and
incubated with β3-CHO, uPAR-CHO, or mock-CHO cells. The
ability of the uPA fragments to support adhesion of these cells was
determined [38].
We propose a model, in which the N-terminal GFD of
uPA binds to uPAR and the kringle domain of uPA binds to
integrins, leading to the uPAR-uPA-integrin ternary complex
on the cell surface. It is likely that the ternary complex for-
mation may be involved in uPA signaling and plasminogen
activation. The isolated kringle or the isolated GFD domain
may suppress uPA signaling or plasminogen activation by
suppressing the process. Indeed isolated kringle domain or
GFD have been shown to suppress tumorigenesis [39].
3. Another Example of the Role of αvβ3 in
uPA Signaling: uPA Kringle and Integrinαvβ3
in Neutrophil Activation
It has been reported that antibody to integrin αvβ3 and RGD
peptide suppress the signaling action of uPA in neutrophils,
although it is unclear if this include direct uPA-αvβ3 inter-
action [40]. The study examined the ability of specific
uPA domains to increase cytokine expression in murine
and human neutrophils stimulated with lipopolysaccharides
(LPS). Whereas the addition of intact uPA to neutrophils
cultured with LPS increased mRNA and protein levels of
interleukin-1β, macrophage-inflammatory protein-2, and
tumor necrosis factor α, deletion of the kringle domain from
uPA resulted in loss of these potentiating effects. Addition of
purified uPA kringle domain to LPS-stimulated neutrophils
increased cytokine expression to a degree comparable with
that produced by single-chain uPA. Inclusion of the RGD
but not the RGE peptide to neutrophil cultures blocked uPA
kringle-induced potentiation of proinflammatory responses,
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Figure 4: Integrin-dependent plasminogen activation on the cell
surface. Parental CHO cells and β3-CHO cells in wells of 96-well
plates were treated with PIPLC to deplete uPAR, and incubated with
wt or delta kringle (ΔK) uPA in the cold binding buffer for
1 h at 4◦C. The cells were washed with the binding buffer, and
plasminogen activation was determined using Glu-plasminogen
and SpectrozymePL chromogenic substrate at 37◦C. We found that
β3-CHO cells showed much higher ability to activate plasminogen
in a manner dependent on the uPA added. Deletion of the
kringle domain (with ΔK-uPA) markedly reduced the plasminogen
activation on β3-CHO, indicating that αvβ3 and uPA-dependent
plasminogen activation required the kringle domain of uPA. These
results suggest that the binding of uPA kringle to integrin αvβ3
induces plasminogen activation [38].
demonstrating that interactions between the kringle domain
and integrins are involved. Antibodies to the αv or β3 subunit
or to αvβ3 heterodimer prevented uPA kringle-induced
enhancement of expression of proinflammatory cytokines
and also of adhesion of neutrophils to the uPA kringle
domain. These results demonstrate that the kringle domain
of uPA, through interaction with αvβ3 integrins, potentiates
neutrophil activation.
4. A Docking Model of uPAR-uPA
Kringle-Integrin Interaction
How does integrin αvβ3 interact with uPA kringle? This has
recently been predicted by docking simulation [41]. They
modeled the interaction of uPA on two integrins, αIIbβ3 in
the open configuration and αvβ3 in the closed configuration.
They found that multiple lowest energy solutions point to an
interaction of the kringle domain of uPA at the boundary
between α and β chains on the surface of the integrins.
This region is not far away from peptides that have been
previously shown to have a biological role in uPAR/integrins
dependent signaling. They demonstrated that in silico dock-
ing experiments can be successfully carried out to identify the
bindingmode of the kringle domain of uPA on the scaffold of
integrins in the open and closed conformation. Importantly
they found that the binding mode is the same on different
integrins and in both configurations. To get a molecular
view of the system is a prerequisite to unravel the complex
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Table 1: Amino acid residues involved in αvβ3-uPA kringle interaction in the docking model. Amino acid residues at the binding interface
(within the 6 Angstrom) were selected using Swiss pdb viewer (v. 4.02).
αv β3 uPA kringle
Ala149, Asp150, Tyr178,
Gln214, Ala215, Ile216,
Asp218, Asp219, Arg248
Tyr122, Ser123, Met124, Lys125, Asp126, Asp127,
Asp179, Met180, Lys181, Thr182, Arg214,
Arg216, Asp217, Ala218, Asp251, Ala252, Lys253,
Thr311, Glu312, Asn313, Val314, Asn316, Val332,
Leu333, Ser334, Met335, Asp336, Ser337
Ser47, Lys48, Thr49, Tyr51, Glu52, Gly53, Asn54,
Gly55, His56, Phe57, Tyr58
Arg59, Tyr84, Asp90, Leu92, Gln93, Leu94,
Asn104, Pro105, Asp106, Asn107, Arg108,
Arg109, Arg110, Glu125
uPA GFD
uPAR
uPA kringle
domain
β3 I-like domain
αvβ-propeller
domain
Figure 5: A model of integrin, uPA kringle, and uPAR complex.
We performed docking simulation of the interaction between uPA
kringle (PDB code 2URK) and integrin αvβ3 (PDB code 1L5G)
using Autodock3. The simulation predicted the poses in which uPA
kringle interacts with αvβ3. The uPA kringle-integrin complex was
superposed with the ATF-uPAR complex (PDB code 2I9B).
protein-protein interactions underlying uPA/uPAR/integrin
mediated cell motility, adhesion, and proliferation, and to
design rational in vitro experiments.
However, in their paper which amino acid residues in
uPA kringle are involved in integrin interaction is unclear.
Thus, we presented ourmodel here (Figure 5).We performed
docking simulation of the interaction between uPA kringle
(PDB code 2URK) and integrin αvβ3 (PDB code 1L5G) using
Autodock3. The simulation predicted the poses in which uPA
kringle interacts with αvβ3 (docking energy−22.3 kcal/mol).
The amino acid residues involved in the interaction are
shown in Table 1. The uPA kringle-binding site in αvβ3
appears to be common to other known αvβ3 ligands. The
uPA kringle-integrin complex was superposed with the
ATF-uPAR complex (PDB code 2I9B). Our model predicts
that integrin αvβ3 and uPAR can bind to ATF (GFD and
kringle) simultaneously without steric hindrance. Obviously,
it would be important to identify amino acid residues in
uPA kringle that are critical for integrin binding by site-
directed mutagenesis. In future studies, using uPA kringles
that cannot bind to integrins or uPAR, it would be important
to study the role of uPA kringle-integrin interaction in the
proinflammatory action of uPA and to establish the role of
uPAR in this process.
5. uPAR-Integrin Interaction
Previous studies suggest that uPAR directly binds to integrins
[42–44]. How can our hypothesis explain this interaction?
Our preliminary docking simulation studies of interaction
between uPAR and integrin αvβ3 did not detect high-affinity
αvβ3 binding sites in uPAR (not shown). In contrast the
docking simulation of interaction between uPA kringle and
αvβ3 predicted high affinity binding of αvβ3 to uPA kringle
(as shown above). Since uPA binds to uPAR at high-affinity
through GFD of uPA, one possibility is that previous studies
detected interactions between the uPA-uPAR complex and
integrins, in which integrins bind indirectly to uPAR through
uPA kringle, but not those between uPAR and integrins. uPA
is widely expressed in different cell types and tissues. This
hypothesis should be rigorously tested in future studies.
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